Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer

被引：3
|
作者：
Datko, F.
D'Andrea, G.
Dickler, M.
Theodoulou, M.
Goldfarb, S.
Lake, D.
Fornier, M.
Modi, S.
Sklarin, N.
Comen, E.
Fasano, J.
Gajria, D.
Drullinsky, P.
Gilewski, T.
Murphy, C.
Syldor, A.
Lau, A.
Hamilton, N.
Patil, S.
Liu, J.
Chandarlapaty, S.
Hudis, C.
Dang, C.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Bon Secours Hosp, Cork, Ireland
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P5-18-20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-18-20
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Datko, Farrah Mikhail
    D'Andrea, Gabriella
    Dickler, Maura N.
    Theodoulou, Maria
    Goldfarb, Shari Beth
    Lake, Diana
    Fornier, Monica Nancy
    Modi, Shanu
    Sklarin, Nancy T.
    Comen, Elizabeth Anne
    Fasano, Julie
    Gajria, Devika
    Drullinsky, Pamela
    Murphy, Conleth G.
    Syldor, Angemael
    Patil, Sujata
    Liu, Jennifer
    Chandarlapaty, Sarat
    Hudis, Clifford
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [2] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
    Datko, Farrah Mikhail
    D'Andrea, Gabriella
    Dickler, Maura N.
    Goldfarb, Shari Beth
    Theodoulou, Maria
    Lake, Diana
    Fornier, Monica Nancy
    Modi, Shanu
    Fasano, Julie
    Comen, Elizabeth Anne
    Gajria, Devika
    Moynahan, Mary Ellen
    Traina, Tiffany A.
    Chen, Melanie
    Hamilton, Nicola
    Patil, Sujata
    Chandarlapaty, Sarat
    Hudis, Clifford
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
    Lyengar, N. M.
    Datko, F. M.
    D'Andrea, G.
    Dickler, M. N.
    Goldfarb, S.
    Theodoulou, M.
    Lake, D.
    Fornier, M. N.
    Modi, S.
    Fasano, J.
    Comen, E.
    Gajria, D.
    Moynahan, M. E.
    Traina, T. A.
    Patil, S.
    Liu, J.
    Jochelson, M.
    Norton, L.
    Hudis, C. A.
    Dang, C. T.
    CANCER RESEARCH, 2013, 73
  • [4] Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
    S Gori
    M Colozza
    A M Mosconi
    E Franceschi
    C Basurto
    R Cherubini
    A Sidoni
    A Rulli
    C Bisacci
    V De Angelis
    L Crinò
    M Tonato
    British Journal of Cancer, 2004, 90 : 36 - 40
  • [5] Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
    Gori, S
    Colozza, M
    Mosconi, AM
    Franceschi, E
    Basurto, C
    Cherubini, R
    Sidoni, A
    Rulli, A
    Bisacci, C
    De Angelis, V
    Crinò, L
    Tonato, M
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 36 - 40
  • [6] Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Hanson, Sarah
    Greco, F. Anthony
    Spigel, David R.
    Barton, John
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (03) : 178 - 183
  • [7] Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result
    Smyth, Lillian Mary
    Iyengar, Neil M.
    Chandarlapaty, Sarat
    Sugarman, Steven
    Comen, Elizabeth Anne
    Drullinsky, Pamela
    Sklarin, Nancy T.
    Traina, Tiffany A.
    Troso-Sandoval, Tiffany A.
    Patil, Sujata
    Wasserheit-Lieblich, Carolyn
    Argolo, Daniel Fontes Santos De Teive E.
    Baselga, Jose
    Norton, Larry
    Hudis, Clifford A.
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study
    Smyth, L. M.
    Iyengar, N. M.
    Chen, M. F.
    Popper, S. M.
    Patil, S.
    Wasserheit-Lieblich, C.
    Argolo, D. F.
    Singh, J. C.
    Chandarlapaty, S.
    Sugarman, S. M.
    Comen, E. A.
    Drullinsky, P. R.
    Traina, T. A.
    Troso-Sandoval, T.
    Baselga, J.
    Norton, L.
    Hudis, C. A.
    Dang, C. T.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 91 - 97
  • [9] Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study
    L. M. Smyth
    N. M. Iyengar
    M. F. Chen
    S. M. Popper
    S. Patil
    C. Wasserheit-Lieblich
    D. F. Argolo
    J. C. Singh
    S. Chandarlapaty
    S. M. Sugarman
    E. A. Comen
    P. R. Drullinsky
    T. A. Traina
    T. Troso-Sandoval
    J. Baselga
    L. Norton
    C. A. Hudis
    C. T. Dang
    Breast Cancer Research and Treatment, 2016, 158 : 91 - 97
  • [10] Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cancer.
    Bernardo, G
    Palumbo, R
    Bernardo, A
    Villani, G
    Melazzini, M
    Poggi, G
    Frascaroli, M
    Jedrychowska, I
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 59S - 59S
12345